The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma

Tan, M; Asad, M; Heong, V; Wong, MK; Tan, TZ; Ye, J; Kuay, KT; Thiery, JP; Scott, C; Huang, RY

Author(s): Tan, M; Asad, M; Heong, V; Wong, MK; Tan, TZ; Ye, J; Kuay, KT; Thiery, JP; Scott, C; Huang, RY;
Details: Publication Year 2019-04,Volume 13,Issue #4,Page 757-780
Journal Title: Molecular Oncology
Publication Type: Journal Article
Abstract: Frizzled family receptor 7 (FZD7), a Wnt signaling receptor, is associated with the maintenance of stem cell properties and cancer progression. FZD7 has emerged as a potential therapeutic target because it is capable of transducing both canonical and non-canonical Wnt signals. In this study, we investigated the regulatory pathway downstream of FZD7 and its functional roles. We found that FZD7 expression was crucial to the maintenance of the mesenchymal phenotype, anoikis resistance, and spheroid and tumour formation in ovarian cancer. We identified TWIST1 as the crucial downstream effector of the FZD7 pathway. TWIST1, a bHLH transcription factor, is known to associate with mesenchymal and cancer stem cell phenotypes. Manipulating TWIST1 expression mimicked the functional consequences observed in the FZD7 model, and overexpression of TWIST1 partially rescued the functional phenotypes abolished by FZD7 knockdown. We further proved that FZD7 regulated TWIST1 expression through epigenetic modifications of H3K4me3 and H3K27ac at the TWIST1 proximal promoter. We also identified that the FZD7-TWIST1 axis regulates the expression of BCL2, a gene that controls apoptosis. Identification of this FZD7-TWIST1-BCL2 pathway reaffirms the mechanism of anoikis resistance in ovarian cancer. We subsequently showed that the FZD7-TWIST1 axis can be targeted by using a small molecule inhibitor of porcupine (PORCN), an enzyme essential for secretion and functional activation of Wnts. In conclusion, our results identified that the FZD7-TWIST1 axis is important for tumorigenesis and anoikis resistance, and therapeutic inhibition results in cell death in ovarian cancers.
Research Division(s): Stem Cells And Cancer
PubMed ID: 30548372
Publisher's Version: https://doi.org/10.1002/1878-0261.12425
Open Access at Publisher's Site: https://doi.org/10.1002/1878-0261.12425
NHMRC Grants: NHMRC/1081178,
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2019-01-14 12:35:29

Last Modified: 2019-04-11 08:37:32